Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

esmo group (esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation solutions, is proud to announce the launch of its latest product—the ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect ... at 29.2 months versus 23 months. The data led to claims that Zynyz plus chemo should be the ...

Jazz Pharmaceuticals plc today announced financial results for the third quarter of 2024 and updated guidance for 2024. "Jazz once again delivered record revenues ...

We'll unveil the top 10 clothing brand logos that have conquered the fashion industry and left an indelible mark on our collective consciousness. If there's one thing that can instantly grab our ...